NetworkNewsBreaks – Lexaria Bioscience Corp. (NA

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own products designated by a national regulator as a medical product, drug, nutraceutical, pharmaceutical or biopharmaceutical, will pay royalty fees to Lexaria for all API powders sold that utilize the DehydraTECH technology. “This strategic alliance with Lexaria Bioscience Corp. underscores the focus of AnodGen to ‘Bring Science to Life,’ in addition to our research and APIs,” said Dr Slimane Aboulkacem, chairman and founding member of AnodGen Bioceuticals.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer